Unassigned

SUPPLEMENTAL INFORMATION DISCLOSURE CITATION

Form PTO-1449 (Modified)

(Use several sheets if necessary)

ATTY. DOCKET NO.	SERIAL NO.
UCSF-085CIP	09/616,223
APPLICANT	
Nade	el, et al.
FILING DATE	GROUP

July 14, 2000

NOV 2 2 2000	_					<u>۱۹۲</u>
The second		是	NOV	2	2 2000	J.
ΨM WY		THE STATE OF THE S	. ∢ }~		, EX	

U.S. PATENT DOCUMENTS

	<u> </u>	<u> </u>				
*Examiner	Document Number	Date	Name	Class	Subclass	Filing Date
Initial			<u></u>			If Appropriate

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Trans	slation
	,					Yes	No
		-					

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

23

AA Grandis et al. (July 24, 1997), "Inhibition of Epidermal Growth Factor Receptor Gene Expression and Function Decreases Proliferation of Head and Neck Squamos Carcinoma but not Normal Mucosal Epithelial Cells."

Oncogene, Vol. 15(4):406-416

EXAMINER DATE CONSIDERED (2/4/0)

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION

Form PTO-1449 (Modified) (t)se several sheets if necessary) ATTY. DOCKET NO. SERIAL NO. UCSF-085 CIP 09/616,223 APPLICANT

NOV 1 3 2000 RADEMA

Nadel et al. **GROUP FILING DATE**

July 14, 2000

Unassigned

U.S. PATENT DOCUMENTS

*Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date
7.3	AN	5,525,625	06/11/96	Bridges et al.			
019	AO	6,037,361	03/14/00	Roth et al.			
		1					

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Trans	slation
13 AF	WO 97/19065	05/29/97	PCT			Yes .	No
JO AC	WO 97/45412	12/04/97	PCT				
AF	WO 98/37881	09/03/98	PCT				
AS	WO 99/01421	01/14/99	PCT				
АТ	WO 99/01426	01/14/99	PCT .				
AL	WO 99/32121	07/01/99	PCT				
AV	WO 00/06560	02/10/00	PCT				
AV	WO 00/06561	02/10/00	PCT				
AX	WO 00/09485	02/24/00	PCT				
AY	WO 00/17162	03/30/00	PCT				

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

Donato et al (1989), "Tumor Necrosis Factor Modulates Epidermal Growth Factor Receptor Phosphorylation and Kinase Activity in Human Tumor Cells", The Journal of Biological Chemistry, Vol. 264(34): 20474-20481.

Desseyn et al. (1997), "Human Mucin Gene MUC5B, the 10.7-kb Large Central Exon Encodes Various Alternate Subdomains Resulting in a Super-repeat", The Journal of Biological Chemistry, Vol. 272(6): 3168-3178.

EXAMINER	2
----------	---

DATE CONSIDERED

EXAMINER: (nitial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

	<u> </u>	Ð∦	VFO	RMATION DISCLOSURE CITATION	ATTY. DOCKET NO. UCSF-085 CIP	SERIAL NO. 09/616,223		
/ ⁽	י כ	' (` _{\(\rangle \)}	Form PTO-1449 (Modified) se several sheets if necessary)		<u></u>		
/			1	B Several sheets if necessary,	APPLICANT Nade	el et al.		
\ <u></u> M0	V 1	3 2	000	当				
A.					FILING DATE July 14, 2000	GROUP Unassigned		
7	PA	JEM		Goldstein et al. (1995), "Biological Efficacy of a Chim				
Y	1	X		in a Human Tumor Xenograft Model", Clinical Cance.		William I		
0	AD Kawamoto et al. (1983), "Growth stimulation of A431 cells by epidermal growth factor: Identification of high affinity receptors fo epidermal growth factor by an anti-receptor monoclonal antibody", <i>Proc. Natl. Acad. Sci USA</i> , Vol. 80: 1337-1341.							
				Kondapaka et al. (1996), "Tyrosine kinase inhibitor as prostate cancer", <i>Molecular and Cellular Endocrinolog</i>		and antiproliferative agent:		
				Levitski (1994), "Signal-transduction therapy, a novel 226(1):1-13.	approach to disease manage	ment", Eur. J. Biochem., Vol.		
				Lorimer, et al. (1995), "Immunotoxins that Target an C Expressed in Human Tumors", Clinical Cancer Reseat		Growth Factor Receptor		
				Petit er al. (1997), "Neutralizing Antibodies against Ep Tyrosine Kinases Down-Regulate Vascular Endothelia in Vivo", American Journal of Pathology, Vol. 151(6):	al Growth Factor Production			
			ΑI	Powis (1994), "Signaling pathways as targets for antic	nticancer drug development", <i>Pharmac. Ther.</i> , Vol. 62:57-95.			
	ļ			Schmidt et al. (1996), "Targeted inhibition of tumour cantibody domain and TGFa", British Journal of Cance	ur cell growth by a bispecific single-chain toxin containing an incer, Vol. 74: 853-862			
				Takeyama et al. (1998), "Neutrophil-dependent goblet adhesion molecules", <i>Am. J. Physiol.</i> , Vol. 275:294-30	plet cell degranulation: role of membrane-bound elastase and -302.			
				Temann et al. (1997), "A Novel Role for Murine IL-4. Mucin Hypersecretion", <i>Am J. Respir. Cell Biol.</i> , Vol.	-4 <i>In Vivo</i> : Induction of MUC5AC Gene Expression and ol. 16:471-478.			
				Ullrich et al. (1984), "Human epidermal growth factor amplified gene in A431 epidermoid carcinoma cells."	or receptor cDNA sequence and aberrant expression of the "Nature, Vol. 309(5967):418-25.			
.,			ΑZ	Brown (1999), "Clinical Studies with matrix metallpro	·			
				Grandis, jr., et al. (1997), "Inhibition of epidermal grodecreases proliferation of head and neck squamous car <i>Oncogene</i> , Vol. 15(4):409-416.	cinoma but not norml mucos	sal epithelial cells."		
				Kumar et al. (1998), "Cooperative interaction of autoon Cell Biology and Toxicology, Vol. 14(4):293-299.		_		
BC Lee et al. (2000), "Leukotriene Receptor Antagonis of Asthmatic Individuals." American Journal of Re. 1886.					iratory and Critical Care Me	edicine, Vol. 161(6):1881-		
	cleavage of proHB-EGF." Nature, Vol. 402:884-88				ion by G-protein-coupled receptors requires metalloproteinase -888.			
	BE Takeyama et al. (1999), "Epidermal growth factor sy of the national Academy of Sciences USA, Vol. 96(6)				3081-3086.			
				Takeyama et al. (2000), "Oxidative stress causes mucin		n of epidermal growth factor		
receptor: role of neutrophils." Journal of Immunology, Vol. 164(3):1546-1552. BG Wojtowicz-Praga et al. (1997), "Matrix metalloproteinase inhibitors." Investigational New Drugs." 15:61-75.						nal New Drugs." Vol.		

F:\forms\word 2k forms\form PTO-1449.doc

EXAMINER	<u>`</u>	DATE CONSIDERED	12/4/01				
			EP 609; Draw line through citation if				
not in conformance and not considered. Include copy of this form with next communication to applicant.							